- Peptide CEPLSLASTPSWNAS, corresponding to amino acid residues 2-15 of rat SSTR5 (Accession P30938). Extracellular, N-terminus.
- Western blot analysis of rat brain lysate:1. Anti-Somatostatin Receptor Type 5 (extracellular) Antibody (#ASR-005), (1:200).
2. Anti-Somatostatin Receptor Type 5 (extracellular) Antibody, preincubated with Somatostatin Receptor Type 5 (extracellular) Blocking Peptide (#BLP-SR005).
- Expression of SSTR5 in mouse cerebellumImmunohistochemical staining of Somatostatin receptor 5 (SSTR5) in mouse cerebellum using Anti-Somatostatin Receptor Type 5 (extracellular) Antibody (#ASR-005). A. SSTR5 (red) appears in Purkinje cells (horizontal arrows) and in molecular layer interneurons (vertical arrows). B. Parvalbumin (green) appears in the Purkinje cells and their processes. C. merge of SSTR5 and parvalbumin demonstrates co-localization in Purkinje cells (horizontal arrows) but not in the molecular layer (vertical cells). DAPI is used as the counterstain (blue).
- Expression of SSTR5 in human HT-29 cellsCell surface detection of SSTR5 in intact living human colorectal adenocarcinoma (HT-29) cells. A. Extracellular staining of cells with Anti-Somatostatin Receptor Type 5 (extracellular) Antibody (#ASR-005), (1:50), (red). B. Merged image of A with live view of cells.
- Patel, Y.C. (1999) Front. Neuroendocrin. 20, 157.
- Weckbecker, G. et al. (2003) Nat. Rev. Drug Discov. 2, 999.
- Culler, M.D. et al. (2002) Ann. Endocrinol. (Paris) 63, 2S5.
- Corleto, V.D. et al. (2004) Dig. Liver Dis. 36, S8.
- Yang, S.K. et al. (2007) Am. J. Physiol. 292, E1863
Somatostatin (SST) is a small cyclic peptide that was first identified as a powerful inhibitor of the secretion of various hormones including growth hormone (GH), thyroid-stimulating hormone (TSH) and prolactin from the pituitary, as well as almost every major hormone from the intestinal tract. SST consists of two major bioactive forms, SST-14 and the N-terminus extended peptide SST-28, that can be produced by a wide variety of neuroendocrine, inflammatory and immune cells. In target cells, SST induces a variety of physiological functions that include neuromodulation, cell secretion, cell proliferation and smooth muscle contractility.
SST acts on its multiple cell targets via a family of six receptors that originate from five genes: SSTR1, SSTR2a, SSTR2b, SSTRR3, SSTR4, SSTR5. The SSTRs are members of the G-protein coupled receptor superfamily and they modulate cell response via multiple second messenger systems such as inhibition of adenylate cyclase, modulation of conductance of ion channels and protein dephosphorylation.
In contrast to SSTR1-4 that bind SST-14 and SST-28 with similar affinity, SSTR5 has a much greater affinity to SST-28 over SST-14.
SSTRs are widely expressed in both the brain and peripheral tissues but with receptor subtype variations between the different cell types.
Strong SSTR expression has been detected in a variety of human tumors including pancreatic, breast, lung and prostate cancers. In fact, SST has been shown to inhibit the growth of various normal and tumor cells. On this basis, several long lasting SST analogs have been developed and are being tested for use in several pathologies such as various cancers, acromegaly, immunoproliferative disorders, diabetic retinopathy, epilepsy and pain.
SSTR5 is expressed in a variety of tissues and cells, including pancreas, colonic mucosa, small intestine, heart, and vascular smooth muscle cells.
SSTR5 has been shown to mediate growth inhibition and cell proliferation, and to play an important role in cancer growth regulation as one of the most potent inhibitory receptors.
Species reactivity key:
Alomone Labs is pleased to offer a highly specific antibody directed against an epitope of rat SSTR5. Anti-Somatostatin Receptor Type 5 (extracellular) Antibody (#ASR-005), can be used in western blot, immunohistochemistry and live cell imaging applications. It has been designed to recognize SSTR5 in human, mouse and rat samples.
- Mouse brain sections (1:1000).
Lukomska, A. et al. (2020) Brain Struct. Funct. 225, 387.